Two Chinese Biopharma Firms Secure Over RMB 100 Million Each in Funding, Advance Product Development and File IPO Prospectuses

　　【Pharmaceutical Network Industry DynamicsAccording to statistics, this week (December 16th-20th) at least 10 companies in China's pharmaceuticals and health sector received financing. These enterprises are mainly involved in fields such as artificial joints, organoid new drugs, and microscopic surgical endoscopes.
 

In terms of single financing amount, TrendTec and WEMT have both reached hundreds of millions of RMB.
 

Specifically, on December 16, TrendTec announced the completion of an equity financing round exceeding 100 million yuan. This round was led by Vivo Capital, with funds managed by CICC Capital participating as followers. The proceeds will be used for production line construction and subsequent product iteration and development.
 

Data shows that TrendTec is a developer of ceramic materials for hip joints, mainly focusing on the research, production, and sales of ceramic materials for hip joints.
 

With the intensification of population aging, the number of patients with joint diseases is increasing, and the projected implantation volume of hip joints will also grow rapidly. After the centralized procurement policy, joint manufacturers have significantly reduced prices. In China, the core components of joints, ceramic femoral heads and liners, are all purchased from abroad, so domestic manufacturers are under tremendous cost pressure. To address this, the Ministry of Industry and Information Technology and the National Medical Products Administration jointly launched the "Open Competition for Innovation Tasks in Biomedical Materials" initiative in 2023 to support the research, development, and application of biomedical materials through policies, financing, commercialization, and other dimensions.
 

TrendTec, as the winning unit for undertaking biomedical ceramic (powdered ceramic) projects, plays a significant role in accelerating the substitution of imports. As of August 2024, TrendTec's powdered ceramic materials have completed the main document filing with the pharmaceutical regulatory authority, meeting the conditions for downstream manufacturers to register. This enables the company to provide downstream manufacturers with more cost-effective material products.
 

WEMT recently announced the completion of an over 100-million-yuan Series B financing round, invested by a leading fund in China. According to reports, the funds from this round will be used to expand the company's multi-pipeline layout in the fields of energy medicine and medical devices, accelerate the production, sales channel expansion, and brand building of core products such as YOUMAGIC®, providing strong financial support for the research, innovation, and market expansion of YOUMAGIC and WEMT.
 

In addition, the reason why this round of investors chose to invest in WEMT, the R&D company of YOUMAGIC, is mainly due to YOUMAGIC®'s innovative technological advantages and market potential in high-energy monopolar radiofrequency technology, as well as WEMT's profound background and strength in the field of energy medicine. Both parties are expected to jointly promote technological progress in the field of energy medicine and accelerate the high-end localization of China-produced alternatives in the medical industry.
 

Moreover, on December 16, AINNOVI announced the completion of a nearly RMB 100 million Series A financing round. This round was co-led by Eyebright Fund and Mountain Blue Capital, with participation from Zero2IPO Ventures and Chongqing Eyebright Spirit. WinX Capital served as the exclusive financial advisor for this transaction and will continue to lead subsequent financing.
 

It is reported that this is a company specializing in microscopySurgical OperationDevelopment of key technologies for scene visual perception and intelligent decision-making, focusing on core product lines such as ultra-high-definition stereoscopic vision technology and intelligent human-computer interaction technology. Building a company development strategy of "computational imaging + industry applications," aspiring to become a leader in precision visual imaging technology and a global provider of high-end medical imaging modules, equipment, and digital surgical solutions. The funds from this round of financing will mainly be used for the research, registration, and market promotion of modular products for surgery and ophthalmology, as well as the development of complete systems for microscopic surgical endoscopes.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.